Nachrichten zur Mirum Pharmaceuticals Inc. Aktie

EQS-News: Mirum Pharmaceuticals übernimmt HBM Portfoliounternehmen Bluejay Therapeutics für bis zu USD 820 Millionen (deutsch)

Mirum Pharmaceuticals übernimmt HBM Portfoliounternehmen Bluejay Therapeutics für bis zu USD 820 Millionen^HBM Healthcare Investments AG / Schlagwort(e): Ankauf/PartnerschaftMirum Pharmaceuticals…

Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026

Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.…

CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?

CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.…

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise By Investing.com

Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise…

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

…

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

…

Mirum Pharmaceuticals misses Q4 earnings, stock falls By Investing.com

Mirum Pharmaceuticals misses Q4 earnings, stock falls…

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do…

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Heres What You Should Know

The mean of analysts price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this…

Mirum Pharmaceuticals (MIRM) is on the Move, Heres Why the Trend Could be Sustainable

Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking…

Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential

…

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

…

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

…

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest…

Mirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten

FOSTER CITY, Kalifornien, USA--(BUSINESS WIRE)--Wie Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) heute mitteilte, hat der europäische Ausschuss für Humanarzneimittel (CHMP) eine…

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

…

Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics)

Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Liver Cirrhosis - Pipeline Insight, 2024" clinical trials has been…

Nachrichten zur Mirum Pharmaceuticals Inc. Aktie

EQS-News: Mirum Pharmaceuticals übernimmt HBM Portfoliounternehmen Bluejay Therapeutics für bis zu USD 820 Millionen (deutsch)

Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026

CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise By Investing.com

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Mirum Pharmaceuticals misses Q4 earnings, stock falls By Investing.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Heres What You Should Know

Mirum Pharmaceuticals (MIRM) is on the Move, Heres Why the Trend Could be Sustainable

Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

Mirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics)

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Mirum Pharmaceuticals COO sells $111k in company stock By Investing.com

Mirum Pharmaceuticals COO sells over $28k in company stock By Investing.com

Mirum Pharmaceuticals CEO sells $106,390 in company stock By Investing.com

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

dpa-AFX ProFeed